Vins Daniel
Research Subjects
Vins Daniel has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anandaram Sreekanth
Department of Chemistry, National Institute of Technology, Tiruchirappalli, India
1 shared publication Cesar Echeverria
1 shared publication- Diego Quezada
Facultad de Ingeniería, Instituto de Ciencias Aplicadas Universidad Autónoma de Chile Santiago Chile
1 shared publication - Jebiti Haribabu
Facultad de Medicina, Universidad de Atacama, Los Carreras 1579, 1532502 Copiapo, Chile
1 shared publication Vipin Singh
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Spectroscopic, Electrochemical, Computational, and Biological Investigation of Cu(II), Ni(II), and Zn(II) Complexes of 3-Pyridinecarboxaldehyde Thiosemicarbazone
The new 3-pyridinecarboxaldehyde-based thiosemicarbazone ligand 3-PCTSC and its Cu(II), Ni(II), and Zn(II) complexes were successfully prepared and well characterized in terms of molecular structure, electronic structure, and biological activity. The DNA and BSA binding were investigated through PL and CV, and found to be strong and spontaneous binding (hypothesized to be static quenching) within the molecules. The binding number was highest for the Ni(II) complexes, elucidated to derive from an elongated conjugated system with more electron cloud density and more charge transfer ability; this trend was borne out in the biological activity studies. Electronic distributions and reactive areas characterized through DFT, the ring structures, and frontier molecular orbital evaluation showed good correlation with the bioactivity results. The molecular dockings against the BSA, DNA, and some cancer target proteins produced binding energies that were very promising, with the Ni(II) compound exhibiting the most thermodynamically favorable binding modes with hydrogen bonding, stacking interactions, and metal adjacent binding modes. ADMET calculations gave all the molecules excellent druglikeness, acceptable lipophilicity, high GI absorption, and no abnormal toxic alerts. Due to all these factors, this Ni(II) derivative was the most cytotoxic in an 'in vitro' screening experiment, and more than ten times the potency of the ligand alone and the other two analogues. In summary, the spectroscopic, electrochemical, computational, and biological data altogether unveil the great anticancer efficacy of the nickel(II) complex.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSpectroscopic, Electrochemical, Computational, and Biological Investigation of Cu(II), Ni(II), and Zn(II) Complexes of 3-Pyridinecarboxaldehyde Thiosemicarbazone
The new 3-pyridinecarboxaldehyde-based thiosemicarbazone ligand 3-PCTSC and its Cu(II), Ni(II), and Zn(II) complexes were successfully prepared and well characterized in terms of molecular structure, electronic structure, and biological activity. The DNA and BSA binding were investigated through PL and CV, and found to be strong and spontaneous binding (hypothesized to be static quenching) within the molecules. The binding number was highest for the Ni(II) complexes, elucidated to derive from an elongated conjugated system with more electron cloud density and more charge transfer ability; this trend was borne out in the biological activity studies. Electronic distributions and reactive areas characterized through DFT, the ring structures, and frontier molecular orbital evaluation showed good correlation with the bioactivity results. The molecular dockings against the BSA, DNA, and some cancer target proteins produced binding energies that were very promising, with the Ni(II) compound exhibiting the most thermodynamically favorable binding modes with hydrogen bonding, stacking interactions, and metal adjacent binding modes. ADMET calculations gave all the molecules excellent druglikeness, acceptable lipophilicity, high GI absorption, and no abnormal toxic alerts. Due to all these factors, this Ni(II) derivative was the most cytotoxic in an 'in vitro' screening experiment, and more than ten times the potency of the ligand alone and the other two analogues. In summary, the spectroscopic, electrochemical, computational, and biological data altogether unveil the great anticancer efficacy of the nickel(II) complex.